Professor Paul Dastoor and his team at the Centre for Organic Electronics developed the device, and are working closely with @gbs_inc on the purpose-built manufacturing facility. Full story here: bit.ly/3xKnxKc

NEWS: $GBS Chief Financial Officer, Spiro Sakiris interview with 2GB Sydney radio, following the $6.3 million grant awarded to $GBS by the Australian Federal Government to commence the manufacturing of our Biosensor technology. #biotechnology #diabetes #diabetestest

Our Saliva Glucose Biosensor featured on Channel 9News Australia earlier this week after $GBS was awarded a $6.3 million grant to create a manufacturing facility that "will help push the project into commercial production." University of Newcastle youtube.com/watch?v=XLGC8C…

This National Diabetes Week, we are unmasking the world’s largest epidemic, Diabetes, to raise awareness about the real impact diabetes-related stigmas have on all aspects of life for people living with this disease. Read more: theiqgroupglobal.com/news/diabetes-… #NDW2021 Diabetes Australia

ICYMI: Australian scientists say they have developed the ‘holy grail’ of blood sugar testing for diabetics reut.rs/3i81Ywg

NEWS: ABC News Radio interview by Fran Kelly with $GBS Inc.’s Scientific Board Member, Professor Paul Dastoor, from the University of Newcastle. In the interview, Professor Dastoor discusses the mechanism behind the innovative technology: youtube.com/watch?v=h5IrCv…

NEWS: $GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test. Read more here: gbs.inc/gbs-inc-engage… #Biotechnology #diabetes #innovation #biosensor

Engineers at MIT and Harvard University have designed a small tabletop device that can detect SARS-CoV-2 from a saliva sample in an hour. In a new study, they showed that the diagnostic is just as accurate as the PCR tests now used. Read more here: sciencedaily.com/releases/2021/…

You might have noticed the purple ribbon in our logo this month in support of #GynecologicCancerAwarenessMonth. September is the time to help bring awareness to all gynecologic cancers. Visit lnkd.in/eat7EFh for more information. #GCAM

NEWS: OncoTEX Inc. appoints Chief Executive Officer, Dr Jonathan Arambula. Read the full announcement here: oncotexinc.com/2021/10/oncote…

NEWS: OncoTEX Inc. is pleased to announce it has received licensing for a gold compound platform technology that induces the body’s immune system to destroy cancer cells. Read the full announcement here: oncotexinc.com/2021/11/gold-t…

NEWS: We are pleased to announce the completion of a clinical validation study showcasing the success of LSBD's rapid SARS-CoV-2 Antibody test. Click here to read the full announcement: theiqgroupglobal.com/news/validatio…

The Biosensor Platform can measure glucose in saliva and is being designed to make painful blood finger-prick testing obsolete. linkedin.com/posts/medtechs…

U.S. oncology company OncoTEX Inc., a subsidiary of The iQ Group Global, has acquired a novel gold compound technology, AuraTEX, that uses the body's immune system to help destroy cancer cells. businessinsider.com.au/how-gold-compo…

Painless glucose monitoring for people living with diabetes. LSBD, a subsidiary of The iQ Group Global, has filed an application with the FDA for Breakthrough Devices Designation for its Saliva Glucose Biosensor. theiqgroupglobal.com/news/fda-break…

.OncoTEX Inc. Inc.'s peer-reviewed Chem Soc Rev submission highlights how the human immune system can be recruited to fight cancer cells using gold-based compounds.

The iQ Group Global is proud to support #worldcancerday by helping #closethecaregap and create a future without cancer.

The Wyss Institute’s eRapid technology was licensed to Antisoma Therapeutics to fast-forward point-of-care diagnostics for infectious, immune, and cancer diseases, including COVID-19. #Diagnostics wyss.harvard.edu/news/harvard-w…

Our medtech member company Antisoma Therapeutics has secured a worldwide license for Wyss Institute's eRapid multiplexed biosensor tech to create a point-of-care diagnostics test platform for COVID-19 & multiple disease biomarkers. #diagnostics #rapidtest theiqgroupglobal.com/news/the-iq-gr…

OncoTEX is proud to celebrate the 65th birthday of pioneer chemist and cancer survivor, Professor Jonathan Sessler. Prof Sessler’s Texaphyrin molecules are the prime components of our TEX Core anticancer drug platform, and will someday help save lives. sciencedirect.com/science/articl…